ALT Q2 2018 Earnings — Altimmune, Inc. Revenue & Financial Results | Market Cap Arena

ALTAltimmune, Inc.

$331M

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+48849.8% YoY

Gross Profit

-$3M-103.5% margin

Operating Income

-$5M-224.9% margin

Net Income

-$9M-378.1% margin

EPS (Diluted)

$-9.56

QoQ Revenue Growth

+48849.8%

Cash Flow

Operating Cash Flow

$348,143

Free Cash Flow

$176,455

Stock-Based Comp.

$252,184

Balance Sheet

Total Assets

$52M

Total Liabilities

$16M

Stockholders' Equity

$36M

Cash & Equivalents

$4M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$4,938	+48849.8%
Gross Profit	-$3M	-$5M	+52.3%
Operating Income	-$5M	-$4M	-35.5%
Net Income	-$9M	-$3M	-193.8%

Revenue Segments

Grant

$2M100%

License and Service

$4,9470%